themacromindset
Posted - 1 month ago
$ZEAL seeks partner for its ‘next generation’ weight loss drug. “Our focus is really what’s needed in the 2030s, and it’s really about establishing the next-generation molecules that are not based on GLP-1s."
YellenonairesClub
Posted - 2 months ago
$ALT Institutions that are seriously about making money want to bet on all horses in the GLP-1/weight loss space, not just $LLY and $NVO $ALT $TERN $GCPR $ZEAL $VKTK ....not all will be winners, but some will make you a TON of money
Jabed206
Posted - 2 months ago
$ZEAL are their product phase 2 or 3?
Biotech2424
Posted - 2 months ago
Lose weight make $$$ get laid.
$TERN $NRBO $VKTX $ZEAL
Biotech2424
Posted - 2 months ago
Ride the Obesity Wave…
Goldman Sachs states it will be $130 billion market in 2030.. The key will be weight loss and minimizing muscle loss. Boom
$GPCR $ZEAL $NRBO $TERN
Biotech2424
Posted - 2 months ago
$NRBO Viking and Altimmune are surging.. see if NeuroBo joins in. Good move all are worth a lot more. $130 billion market in 2030.
$VKTX $ALT $ZEAL
Biotech2424
Posted - 2 months ago
$ZEAL Wall street target price versus actual price on NASDAQ listed GLP's. I am bullish on all of these. Goldman Sachs says it will be $130 billion market by 2030. $ALT $GPCR $NRBO $VKTG $CRBP
SeekingOctane
Posted - 2 months ago
$NRBO NeuroBo looking like the next Viking or Zealand in glp1 arena… phase 1 obesity data due end of month.
$VKTX $ZEAL $SMMT
BearBullyJack
Posted - 2 months ago
$VKTX looks like $ZEAL release Phase1b data as well
BearBullyJack
Posted - 2 months ago
$VKTX yea the market so far seems unimpressed, even $ZEAL popped 4% on this news
BearBullyJack
Posted - 2 months ago
$VKTX very interesting seeing the digestion pre market. It looks like a sell off in Tern with people taking profits and redistributing into $ALT and $VKTX. I find it interesting that $GPCR and $ZEAL aren’t seeing any positive movements. Definitely goes to show who holds what and where conviction lies right now headed into more catalysts
BearBullyJack
Posted - 08/22/24
$VKTX $ALT $TERN $ZEAL $GPCR This doesn’t even account for the fact that the retail investors on these boards are an even smaller fraction of the retail part of the pie. We’re talking about paying a couple dozens of people to do what? Get maybe 20,000 shares?
BearBullyJack
Posted - 08/22/24
$VKTX $ALT $TERN $ZEAL $GPCR I’m confused where this thing came from where people are under this strange belief that bears on these boards are paid by someone. You gotta be dumb as rocks to think someone is going to pay someone money to try to create retail fear for stocks that literally have no sway in the price action from their fractional % of the float compared to institutional investors. From a business perspective that’s a terrible business model from a risk/reward standpoint.
sageinvestor
Posted - 3 months ago
@slayer70 @Milano14 still lots of upside . Look at $vktx or $zeal . Novel mechanisms in obesity that work are with billions
yus37
Posted - 4 months ago
$VKTX $ALT $TERN $GPCR $ZEAL $100 billion. That’s how much the weight loss drug market will be worth by 2030, according to some analysts. Some think the market is potentially worth much more—some forecasts have grown to around $150 billion by the early 2030s—and both Novo and Lilly raked in billions from their GLP-1 drugs last year (which are also used to treat diabetes)
https://www.forbes.com/sites/roberthart/2024/07/16/ozempic-and-wegovy-rivals-here-are-the-companies-working-on-competitor-weight-loss-drugs/
Brent24
Posted - 4 months ago
@golfeveryday @Neo_the_Cat @CowPie_7bilORWifeLeaveMe $ZEAL market cap is mainly based off of Petrelintide. Survo is partnered out. The big difference is Petrelintide is a completely diff mechanism of action so may have REAL advantages over GLP1 drugs. Even combined GLPs. $VKTX $LLY $NVO $ALT $ZLDPF
yus37
Posted - 4 months ago
$LLY $NVO $VKTX $ZEAL $AMGN The obesity market could reach hundreds of billions by 2034, with some experts predicting a trillion-dollar opportunity in the next 10 years, driven by the potential of GLP-1 drugs. For those interested, there is excellent research from #Stifel on all the players in this very lucrative market opportunity. https://dealforma.com/stifel-update-on-the-future-of-the-obesity-pharmaceutical-market-july-8-2024/
Slapshot22
Posted - 4 months ago
@Water03 Zealand pharma $ZEAL i believe just had some positive news on their drug clinic. multiple companies going after the prize here, not just 2.
Oknrv
Posted - 06/22/24
@Slapshot22 I am not interested in $ZEAL nor am I into selling you or convincing you (of) anything. Cheers!
Oknrv
Posted - 06/22/24
@Braverabbit I saw a picture of a slide somewhere on twitter for the drug cohorts (not the placebo). Search $ZEAL on twitter. I myself lost interest.
Oknrv
Posted - 06/22/24
$VKTX So $ZEAL Petrelintide = cagrilintide
TrustButVerifi
Posted - 06/22/24
$VKTX I don't understand why folks here who have same access do Not post updates? It helps your goal! WTF From pharmDca on X: part 1 ) For oral- We are the only one with both SubQ and Oral drugs that have combo with glp and gip mechanisms and that is the key difference between us and other drugs 2) dosing beyond QD on oral- yes because the half life is over 200 hours. We thought about it. transition to weekly dosing, will drastically reduce the amount of material needed which was overblown by some to bring down stock price 3) Brian killed that bearish thesis by saying weekly and monthly dosing require way less material 4) we don't need that capacity now and by the time we need it we will have plenty. 5) so fda comments at july earnings meeting If ph2B- They will pursue monthly regimen 6) When asked about $ZEAL recent data, Brian said our data is very competitive
aheh
Posted - 5 months ago
Weight loss drugs will be on market shared with $LLY $NVO $ZEAL $ALT
fda_tracker
Posted - 6 months ago
$ZEAL New PDUFA Date 2024-10-08 Zealand Pharma Link:https://www.globenewswire.com/news-release/2024/05/16/2883075/0/en/Zealand-Pharma-Announces-Financial-Results-for-the-First-Quarter-of-2024.html Calendar:http://www.fdatracker.com/fda-calendar/
fda_tracker
Posted - 6 months ago
$ZEAL New PDUFA Date 2024-12-22 Zealand Pharma Link:https://www.globenewswire.com/news-release/2024/05/16/2883075/0/en/Zealand-Pharma-Announces-Financial-Results-for-the-First-Quarter-of-2024.html Calendar:http://www.fdatracker.com/fda-calendar/
milkenmike
Posted - 6 months ago
$ZEAL $ELAB
A lot of new players entering the obesity space. There’s lots of pitfalls with the current class of drugs. This is one to watch; initial clinical results are promising. Adding a myostatin blocker seems like a prudent approach. Ask any plastic surgeon, ozempic face is a huge problem that needs a fix and the aesthetic issues are really the tip of the overall health picture. https://finance.yahoo.com/news/elevai-labs-acquires-exclusive-license-130000444.html
BTECHINV
Posted - 04/24/24
$ALT $xbi Validating the long hypothesized medical science view highlighted in Nature Reviews over a decade ago could make Pemvidutide THE GLP-1 leader in Obesity as no one does Glucagon agonism better than PEMVI in my opinion. Once PEMVI (and Survo $zeal) hit the market, very tough for other GCGR/GLP-1 candidates to follow/differentiate. Company alluded to energy expenditure in March ER call. (GLP-1 agonism alone does NOT provide this effect.) ..."We think this would also represent a fundamental effect of glucagon on intermediary metabolism and energy expenditure that could continue in the future basically changing the metabolic balance and having in that score, real differentiation from the GLP-1s and the GIPs. We don't have that data at this point. It certainly would be of great interest to study this going forward, and it's something that we're strongly considering in our Phase III program." Long Altimmune (GLP-1/GlucagonR), not medical/investment advice.
